Saba Capital Management’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-1,240,593
Closed -$12.7M – 647
2023
Q2
$12.7M Sell
1,240,593
-17,684
-1% -$180K 0.33% 77
2023
Q1
$12.7M Hold
1,258,277
– – 0.24% 134
2022
Q4
$12.6M Hold
1,258,277
– – 0.17% 198
2022
Q3
$12.2M Hold
1,258,277
– – 0.14% 267
2022
Q2
$12.2M Buy
1,258,277
+138,000
+12% +$1.34M 0.14% 246
2022
Q1
$10.9M Buy
+1,120,277
New +$10.8M 0.16% 209

Saba Capital Management's DALS Position: Q3 2023 in Review

Saba Capital Management sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q3 2023, closing a stake of 1,240,593 shares — an estimated $12.7M sold.

Saba Capital Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $12.7M in Q1 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • Saba Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q3 2023 after selling out during the quarter.
  • Saba Capital Management sold 1,240,593 DA32 Life Science Tech Acquisition Corp shares in Q3 2023, an estimated $12.7M.
  • Saba Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp in Q1 2022 and held it in 6 quarters.
  • Saba Capital Management's DA32 Life Science Tech Acquisition Corp position peaked at $12.7M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q3 2023.

Based on Saba Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.